Next Article in Journal
Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19
Next Article in Special Issue
Biologics for Reducing Cardiovascular Risk in Psoriasis Patients
Previous Article in Journal
Three Visual–Diagnostic Methods for the Detection of Enamel Cracks: An In Vitro Study
Previous Article in Special Issue
Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
 
 
Article
Peer-Review Record

Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis

J. Clin. Med. 2023, 12(3), 974; https://doi.org/10.3390/jcm12030974
by Teppei Hagino 1,*, Hidehisa Saeki 2 and Naoko Kanda 1
Reviewer 1: Anonymous
Reviewer 2:
J. Clin. Med. 2023, 12(3), 974; https://doi.org/10.3390/jcm12030974
Submission received: 19 December 2022 / Revised: 21 January 2023 / Accepted: 23 January 2023 / Published: 27 January 2023

Round 1

Reviewer 1 Report

Point 1: Line 9: In the abstract, you must include an introduction (1 or 2 sentences) that summarizes your topic and highlights the purpose of the study. Also, the type of study

 

Point 2: references 1 and 2 are the same

 

Point 3: line 44-46 make it fluent: It has been reported that baseline NLR and PLR before treatment may predict TNF- inhibitor treatment outcomes in patients with rheumatoid arthritis; higher baseline NLR and PLR were associated with non-response to TNF- inhibitors at week 12.

 

Point 4: line 51 add Biomarkers definition according to the National Institutes of Health Biomarkers Definitions Working Group,

 

Point 5: study design and data collection: Ideally, a section describing Standard treatment schemes should be included.

 

Pint 6: If you could highlight the most important findings in the table

Point 7: 317 add reference 

Point 8: Add a section on the relevance of the study

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The manuscript is very interesting and provides useful and simple to use methods to predict therapeutic response to anti-TNF-a.

The main question addressed by the research is to define patient's background and biomarkers to predict efficacy and response to biological treatment with anti-TNF-a in psoriasis.

 

Is it relevant and useful as those biomarkers proposed are routinely used or not very difficult to obtain

 

The topic is original and pragmatic especially now when sanitary costs are quite well considered: this study really helps clinician choosing the most suitable biologic for each patient.

 

The research adds more insights in this topic and new evidence especially on regards of scalp psoriasis and CPR use.

 

The paper is well written and the text is clear to read and understand.

 

Then, the conclusions are consistent with the evidence and the arguments presented.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop